Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA).
| Abstract Titles and Presenters | Presentation Details | |
| NXP800 | NXP800, a novel, small molecule GCN2 kinase activator, demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft models Presenter: Ramez N. Eskander Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences University of California San Diego La Jolla, CA, USA | Session Title Poster Session A Session Type Poster Session Date / Time November 16th, 7:30-9:00 PM |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating its potential to treat platinum resistant, ARID1a-mutated ovarian carcinoma. The FDA granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule SRC/YES1 kinase family (SFK) inhibitor currently in a Phase 1a dose escalation clinical trial.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.42 |
| Daily Change: | 0.32 5.25 |
| Daily Volume: | 139,041 |
| Market Cap: | US$124.030M |
December 10, 2024 November 05, 2024 October 23, 2024 September 05, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
